EuroPCR 2018: Real-World TAVR Data Show Consistent Performance With Edwards, Abbott, And Medtronic's Systems

23 May 2018

• By Catherine Longworth

New real-world data on Edward Lifesciences real-world data for its transcatheter aortic valve replacement Sapien 3 valve are among the highlights from the early Hot Line/Late-Breaking Trial sessions at the EuroPCR conference in Paris.

MT1805_Eiffel Tower_710380270 _1200 — EuroPCR 2018 is held in Paris, France on May 22-25

EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), featured a series of presentations of new "real-world" data on transcatheter aortic valve systems during a May 22 Late-Breaking Trial session, including new outcomes with Edwards Lifesciences Corp.'s Sapien 3, Abbott Laboratories Inc.'s Portico, and Medtronic PLC's CoreValve Evolut R.

Edwards' Sapien 3 transcatheter aortic valve is performing as well in the real-world intermediate surgical-risk patients as it did...